FDA approves Keytruda as adjuvant treatment for kidney cancer

木曜日, the federal health agency gave the nod to use Keytruda for the adjuvant treatment in patients with RCC who are considered at Intermediate-High or High Risk of recurrence of the disease following nephrectomy, or nephrectomy and resection of metastatic lesions, リリースは言った. The approval followed results of the pivotal Phase 3 KEYNOTE-564 trial study, in which Keytruda showed a significant reduction in the risk of disease recurrence or death by 32 percent compared to placebo.

The first sign of the disease is often a kidney stone, per the Mayo Clinic. (イチジク)

The first sign of the disease is often a kidney stone, per the Mayo Clinic. (イチジク)

カテゴリー:

i898

タグ:

, , , , ,

コメントは締め切りました.